Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 9/20 | 0.47 |
| ▸ | PLG | P00747 | 4/20 | 0.47 |
| ▸ | PLAU | P00749 | 4/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.47 |
| ▸ | F10 | P00742 | 14/20 | 0.47 |
| ▸ | PLAT | P00750 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25017317 | 0.98 | PRSS1 (0.47) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015709 | 0.91 | PLAU (0.49) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015851 | 0.89 | PLG (0.47) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015847 | 0.88 | PLG (0.47) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015690 | 0.88 | F10 (0.44) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015845 | 0.87 | F10 (0.55) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL21822169 | 0.86 | MAPT (0.52) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015710 | 0.84 | KCNQ3 (0.46) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25015697 | 0.84 | ECE1 (0.42) | PRSS1PLGPLAUKLKB1F2 | |
| SCHEMBL25016725 | 0.84 | F10 (0.44) | PRSS1PLGPLAUKLKB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | PRSS1 39/4885PLG 225/4885PLAU 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.